Skip to main content
Erschienen in: High Blood Pressure & Cardiovascular Prevention 4/2019

01.08.2019 | Review article

Inflammation and Vascular Ageing: From Telomeres to Novel Emerging Mechanisms

verfasst von: Martina Chiriacò, Georgios Georgiopoulos, Emiliano Duranti, Luca Antonioli, Ilaria Puxeddu, Monica Nannipieri, Javier Rosada, Corrado Blandizzi, Stefano Taddei, Agostino Virdis, Stefano Masi

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular disease (CVD) remains the leading cause of morbility and mortality worldwide. The identification of common cardiovascular risk factors has led to the development of effective treatments that enabled a significant reduction of the global cardiovascular disease burden. However, a significant proportion of cardiovascular risk remains unexplained by these risk factors leaving many individuals at risk of cardiovascular events despite good control of the risk factors. Recent randomized clinical trials and Mendelian randomization studies have suggested that inflammation explains a significant proportion of the residual cardiovascular risk in subjects with good control of risk factors. An accelerated process of vascular ageing is increasingly recognized as a potential mechanism by which inflammation might increase the risk of CVD. In turn, cellular ageing represents an important source of inflammation within the vascular wall, potentially creating a vicious cycle that might promote progression of atherosclerosis, independently from the individual cardiovascular risk factor burden. In this review, we summarise current evidence suggesting a role for biological ageing in CVD and how inflammation might act as a key mediator of this association.
Literatur
1.
Zurück zum Zitat Franceschi C, et al. Inflammaging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54.CrossRefPubMed Franceschi C, et al. Inflammaging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54.CrossRefPubMed
2.
Zurück zum Zitat Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc. 1993;41(2):176–81.CrossRefPubMed Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc. 1993;41(2):176–81.CrossRefPubMed
3.
Zurück zum Zitat Bruunsgaard H, et al. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci. 1999;54(7):M357–64.CrossRefPubMed Bruunsgaard H, et al. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci. 1999;54(7):M357–64.CrossRefPubMed
4.
Zurück zum Zitat Hager K, et al. Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging. 1994;15(6):771–2.CrossRefPubMed Hager K, et al. Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging. 1994;15(6):771–2.CrossRefPubMed
5.
Zurück zum Zitat Paolisso G, et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol. 1998;275(2 Pt 1):E294–9.PubMed Paolisso G, et al. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol. 1998;275(2 Pt 1):E294–9.PubMed
6.
Zurück zum Zitat Cohen HJ, et al. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci. 1997;52(4):M201–8.CrossRefPubMed Cohen HJ, et al. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci. 1997;52(4):M201–8.CrossRefPubMed
7.
Zurück zum Zitat Fagiolo U, et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol. 1993;23(9):2375–8.CrossRefPubMed Fagiolo U, et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol. 1993;23(9):2375–8.CrossRefPubMed
8.
Zurück zum Zitat Ferrucci L, et al. The origins of age-related proinflammatory state. Blood. 2005;105(6):2294–9.CrossRefPubMed Ferrucci L, et al. The origins of age-related proinflammatory state. Blood. 2005;105(6):2294–9.CrossRefPubMed
10.
Zurück zum Zitat Rossiello F, et al. DNA damage response inhibition at dysfunctional telomeres by modulation of telomeric DNA damage response RNAs. Nat Commun. 2017;8:13980.CrossRefPubMedPubMedCentral Rossiello F, et al. DNA damage response inhibition at dysfunctional telomeres by modulation of telomeric DNA damage response RNAs. Nat Commun. 2017;8:13980.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Astrup AS, et al. Telomere length predicts all-cause mortality in patients with type 1 diabetes. Diabetologia. 2010;53(1):45–8.CrossRefPubMed Astrup AS, et al. Telomere length predicts all-cause mortality in patients with type 1 diabetes. Diabetologia. 2010;53(1):45–8.CrossRefPubMed
12.
Zurück zum Zitat Bakaysa SL, et al. Telomere length predicts survival independent of genetic influences. Aging Cell. 2007;6(6):769–74.CrossRefPubMed Bakaysa SL, et al. Telomere length predicts survival independent of genetic influences. Aging Cell. 2007;6(6):769–74.CrossRefPubMed
13.
Zurück zum Zitat Cawthon RM, et al. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361(9355):393–5.CrossRefPubMed Cawthon RM, et al. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361(9355):393–5.CrossRefPubMed
14.
Zurück zum Zitat Deelen J, et al. Leukocyte telomere length associates with prospective mortality independent of immune-related parameters and known genetic markers. Int J Epidemiol. 2014;43(3):878–86.CrossRefPubMedPubMedCentral Deelen J, et al. Leukocyte telomere length associates with prospective mortality independent of immune-related parameters and known genetic markers. Int J Epidemiol. 2014;43(3):878–86.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Brouilette SW, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case–control study. Lancet. 2007;369(9556):107–14.CrossRefPubMed Brouilette SW, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case–control study. Lancet. 2007;369(9556):107–14.CrossRefPubMed
16.
Zurück zum Zitat Gardner JP, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005;111(17):2171–7.CrossRefPubMed Gardner JP, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005;111(17):2171–7.CrossRefPubMed
17.
Zurück zum Zitat Zhan Y, et al. Telomere length shortening and alzheimer disease—a Mendelian randomization study. JAMA Neurol. 2015;72(10):1202–3.CrossRefPubMed Zhan Y, et al. Telomere length shortening and alzheimer disease—a Mendelian randomization study. JAMA Neurol. 2015;72(10):1202–3.CrossRefPubMed
18.
Zurück zum Zitat Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–64.CrossRefPubMed Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–64.CrossRefPubMed
19.
Zurück zum Zitat Aviv A. Leukocyte telomere length, hypertension, and atherosclerosis: are there potential mechanistic explanations? Hypertension. 2009;53(4):590–1.CrossRefPubMed Aviv A. Leukocyte telomere length, hypertension, and atherosclerosis: are there potential mechanistic explanations? Hypertension. 2009;53(4):590–1.CrossRefPubMed
21.
Zurück zum Zitat Yui J, Chiu CP, Lansdorp PM. Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood. 1998;91(9):3255–62.PubMed Yui J, Chiu CP, Lansdorp PM. Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood. 1998;91(9):3255–62.PubMed
22.
23.
Zurück zum Zitat von Zglinicki T. Role of oxidative stress in telomere length regulation and replicative senescence. Ann N Y Acad Sci. 2000;908:99–110.CrossRef von Zglinicki T. Role of oxidative stress in telomere length regulation and replicative senescence. Ann N Y Acad Sci. 2000;908:99–110.CrossRef
24.
Zurück zum Zitat Masi S, et al. Association between short leukocyte telomere length, endotoxemia, and severe periodontitis in people with diabetes: a cross-sectional survey. Diabetes Care. 2014;37(4):1140–7.CrossRefPubMed Masi S, et al. Association between short leukocyte telomere length, endotoxemia, and severe periodontitis in people with diabetes: a cross-sectional survey. Diabetes Care. 2014;37(4):1140–7.CrossRefPubMed
25.
Zurück zum Zitat Masi S, et al. Oxidative stress, chronic inflammation, and telomere length in patients with periodontitis. Free Radic Biol Med. 2011;50(6):730–5.CrossRefPubMed Masi S, et al. Oxidative stress, chronic inflammation, and telomere length in patients with periodontitis. Free Radic Biol Med. 2011;50(6):730–5.CrossRefPubMed
26.
Zurück zum Zitat Bekaert S, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell. 2007;6(5):639–47.CrossRefPubMed Bekaert S, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell. 2007;6(5):639–47.CrossRefPubMed
30.
Zurück zum Zitat Usui F, et al. Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35(1):127–36.CrossRefPubMed Usui F, et al. Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35(1):127–36.CrossRefPubMed
31.
Zurück zum Zitat Masi S, et al. Mitochondrial oxidative stress, endothelial function and metabolic control in patients with type II diabetes and periodontitis: a randomised controlled clinical trial. Int J Cardiol. 2018;271:263–8.CrossRefPubMedPubMedCentral Masi S, et al. Mitochondrial oxidative stress, endothelial function and metabolic control in patients with type II diabetes and periodontitis: a randomised controlled clinical trial. Int J Cardiol. 2018;271:263–8.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Giorgio M, et al. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell. 2005;122(2):221–33.CrossRefPubMed Giorgio M, et al. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell. 2005;122(2):221–33.CrossRefPubMed
33.
34.
Zurück zum Zitat Kumar S, et al. Sirtuin1-regulated lysine acetylation of p66Shc governs diabetes-induced vascular oxidative stress and endothelial dysfunction. Proc Natl Acad Sci USA. 2017;114(7):1714–9.CrossRefPubMedPubMedCentral Kumar S, et al. Sirtuin1-regulated lysine acetylation of p66Shc governs diabetes-induced vascular oxidative stress and endothelial dysfunction. Proc Natl Acad Sci USA. 2017;114(7):1714–9.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Zhou S, et al. Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res. 2011;109(6):639–48.CrossRefPubMed Zhou S, et al. Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res. 2011;109(6):639–48.CrossRefPubMed
37.
Zurück zum Zitat Xie J, Zhang X, Zhang L. Negative regulation of inflammation by SIRT1. Pharmacol Res. 2013;67(1):60–7.CrossRefPubMed Xie J, Zhang X, Zhang L. Negative regulation of inflammation by SIRT1. Pharmacol Res. 2013;67(1):60–7.CrossRefPubMed
38.
Zurück zum Zitat De Bonis ML, Ortega S, Blasco MA. SIRT1 is necessary for proficient telomere elongation and genomic stability of induced pluripotent stem cells. Stem Cell Rep. 2014;2(5):690–706.CrossRef De Bonis ML, Ortega S, Blasco MA. SIRT1 is necessary for proficient telomere elongation and genomic stability of induced pluripotent stem cells. Stem Cell Rep. 2014;2(5):690–706.CrossRef
40.
Zurück zum Zitat Goronzy JJ, Shao L, Weyand CM. Immune aging and rheumatoid arthritis. Rheum Dis Clin N Am. 2010;36(2):297–310.CrossRef Goronzy JJ, Shao L, Weyand CM. Immune aging and rheumatoid arthritis. Rheum Dis Clin N Am. 2010;36(2):297–310.CrossRef
41.
Zurück zum Zitat Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):693–704.CrossRefPubMed Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):693–704.CrossRefPubMed
42.
Zurück zum Zitat Hippisley-Cox J, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–82.CrossRefPubMedPubMedCentral Hippisley-Cox J, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–82.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Lindhardsen J, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70(6):929–34.CrossRefPubMed Lindhardsen J, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70(6):929–34.CrossRefPubMed
44.
Zurück zum Zitat van Halm VP, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis. 2009;68(9):1395–400.CrossRefPubMed van Halm VP, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis. 2009;68(9):1395–400.CrossRefPubMed
45.
Zurück zum Zitat Agca R, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17–28.CrossRefPubMed Agca R, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17–28.CrossRefPubMed
46.
Zurück zum Zitat Steer SE, et al. Reduced telomere length in rheumatoid arthritis is independent of disease activity and duration. Ann Rheum Dis. 2007;66(4):476–80.CrossRefPubMed Steer SE, et al. Reduced telomere length in rheumatoid arthritis is independent of disease activity and duration. Ann Rheum Dis. 2007;66(4):476–80.CrossRefPubMed
47.
Zurück zum Zitat Gamal RM, et al. Telomere dysfunction-related serological markers and oxidative stress markers in rheumatoid arthritis patients: correlation with diseases activity. Clin Rheumatol. 2018;37(12):3239–46.CrossRefPubMed Gamal RM, et al. Telomere dysfunction-related serological markers and oxidative stress markers in rheumatoid arthritis patients: correlation with diseases activity. Clin Rheumatol. 2018;37(12):3239–46.CrossRefPubMed
50.
Zurück zum Zitat Morigi M, et al. Leukocyte–endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Investig. 1998;101(9):1905–15.CrossRefPubMedPubMedCentral Morigi M, et al. Leukocyte–endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Investig. 1998;101(9):1905–15.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Singer G, Granger DN. Inflammatory responses underlying the microvascular dysfunction associated with obesity and insulin resistance. Microcirculation. 2007;14(4–5):375–87.CrossRefPubMed Singer G, Granger DN. Inflammatory responses underlying the microvascular dysfunction associated with obesity and insulin resistance. Microcirculation. 2007;14(4–5):375–87.CrossRefPubMed
52.
Zurück zum Zitat Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev. 2009;5(2):120–44.CrossRefPubMed Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev. 2009;5(2):120–44.CrossRefPubMed
53.
Zurück zum Zitat Hinokio Y, et al. Urinary excretion of 8-oxo-7, 8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia. 2002;45(6):877–82.CrossRefPubMed Hinokio Y, et al. Urinary excretion of 8-oxo-7, 8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia. 2002;45(6):877–82.CrossRefPubMed
54.
Zurück zum Zitat Loft S, et al. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis. 1992;13(12):2241–7.CrossRefPubMed Loft S, et al. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis. 1992;13(12):2241–7.CrossRefPubMed
55.
Zurück zum Zitat Sampson MJ, et al. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care. 2006;29(2):283–9.CrossRefPubMed Sampson MJ, et al. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care. 2006;29(2):283–9.CrossRefPubMed
56.
Zurück zum Zitat Masi S, et al. Telomere length, antioxidant status and incidence of ischaemic heart disease in type 2 diabetes. Int J Cardiol. 2016;216:159–64.CrossRefPubMedPubMedCentral Masi S, et al. Telomere length, antioxidant status and incidence of ischaemic heart disease in type 2 diabetes. Int J Cardiol. 2016;216:159–64.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Salpea KD, et al. Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis. 2010;209(1):42–50.CrossRefPubMedPubMedCentral Salpea KD, et al. Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis. 2010;209(1):42–50.CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Humphrey LL, et al. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. J Gen Intern Med. 2008;23(12):2079–86.CrossRefPubMedPubMedCentral Humphrey LL, et al. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. J Gen Intern Med. 2008;23(12):2079–86.CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Janket SJ, et al. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95(5):559–69.CrossRefPubMed Janket SJ, et al. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95(5):559–69.CrossRefPubMed
60.
Zurück zum Zitat Lafon A, et al. Periodontal disease and stroke: a meta-analysis of cohort studies. Eur J Neurol. 2014;21(9):1155–61, e66–7. Lafon A, et al. Periodontal disease and stroke: a meta-analysis of cohort studies. Eur J Neurol. 2014;21(9):1155–61, e66–7.
61.
Zurück zum Zitat Mustapha IZ, et al. Markers of systemic bacterial exposure in periodontal disease and cardiovascular disease risk: a systematic review and meta-analysis. J Periodontol. 2007;78(12):2289–302.CrossRefPubMed Mustapha IZ, et al. Markers of systemic bacterial exposure in periodontal disease and cardiovascular disease risk: a systematic review and meta-analysis. J Periodontol. 2007;78(12):2289–302.CrossRefPubMed
62.
Zurück zum Zitat Tonetti MS, Van Dyke TE, E.F.P.A.A.P.W. Working group 1 of the joint. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Clin Periodontol. 2013;40(Suppl 14):S24–9.PubMed Tonetti MS, Van Dyke TE, E.F.P.A.A.P.W. Working group 1 of the joint. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Clin Periodontol. 2013;40(Suppl 14):S24–9.PubMed
63.
Zurück zum Zitat D’Aiuto F, et al. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol. 2018;6(12):954–65.CrossRefPubMed D’Aiuto F, et al. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol. 2018;6(12):954–65.CrossRefPubMed
64.
Zurück zum Zitat D’Aiuto F, et al. Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. J Dent Res. 2005;84(3):269–73.CrossRefPubMed D’Aiuto F, et al. Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. J Dent Res. 2005;84(3):269–73.CrossRefPubMed
65.
Zurück zum Zitat D’Aiuto F, Orlandi M, Gunsolley JC. Evidence that periodontal treatment improves biomarkers and CVD outcomes. J Clin Periodontol. 2013;40(Suppl 14):S85–105.CrossRefPubMed D’Aiuto F, Orlandi M, Gunsolley JC. Evidence that periodontal treatment improves biomarkers and CVD outcomes. J Clin Periodontol. 2013;40(Suppl 14):S85–105.CrossRefPubMed
66.
Zurück zum Zitat Teeuw WJ, et al. Treatment of periodontitis improves the atherosclerotic profile: a systematic review and meta-analysis. J Clin Periodontol. 2014;41(1):70–9.CrossRefPubMed Teeuw WJ, et al. Treatment of periodontitis improves the atherosclerotic profile: a systematic review and meta-analysis. J Clin Periodontol. 2014;41(1):70–9.CrossRefPubMed
67.
Zurück zum Zitat Tonetti MS, et al. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356(9):911–20.CrossRefPubMed Tonetti MS, et al. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356(9):911–20.CrossRefPubMed
68.
Zurück zum Zitat Wang X, et al. The effect of periodontal treatment on hemoglobin a1c levels of diabetic patients: a systematic review and meta-analysis. PLoS One. 2014;9(9):e108412.CrossRefPubMedPubMedCentral Wang X, et al. The effect of periodontal treatment on hemoglobin a1c levels of diabetic patients: a systematic review and meta-analysis. PLoS One. 2014;9(9):e108412.CrossRefPubMedPubMedCentral
69.
Zurück zum Zitat Sanders AE, et al. Telomere length attrition and chronic periodontitis: an ARIC Study nested case–control study. J Clin Periodontol. 2015;42(1):12–20.CrossRefPubMed Sanders AE, et al. Telomere length attrition and chronic periodontitis: an ARIC Study nested case–control study. J Clin Periodontol. 2015;42(1):12–20.CrossRefPubMed
70.
Zurück zum Zitat Benetos A, et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension. 2001;37(2 Pt 2):381–5.CrossRefPubMed Benetos A, et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension. 2001;37(2 Pt 2):381–5.CrossRefPubMed
71.
Zurück zum Zitat Benetos A, et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension. 2004;43(2):182–5.CrossRefPubMed Benetos A, et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension. 2004;43(2):182–5.CrossRefPubMed
72.
Zurück zum Zitat Demissie S, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell. 2006;5(4):325–30.CrossRefPubMed Demissie S, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell. 2006;5(4):325–30.CrossRefPubMed
73.
Zurück zum Zitat Fitzpatrick AL, et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol. 2007;165(1):14–21.CrossRefPubMed Fitzpatrick AL, et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol. 2007;165(1):14–21.CrossRefPubMed
74.
75.
Zurück zum Zitat Aviv A, et al. Menopause modifies the association of leukocyte telomere length with insulin resistance and inflammation. J Clin Endocrinol Metab. 2006;91(2):635–40.CrossRefPubMed Aviv A, et al. Menopause modifies the association of leukocyte telomere length with insulin resistance and inflammation. J Clin Endocrinol Metab. 2006;91(2):635–40.CrossRefPubMed
76.
Zurück zum Zitat Valdes AM, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366(9486):662–4.CrossRefPubMed Valdes AM, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366(9486):662–4.CrossRefPubMed
77.
Zurück zum Zitat Al-Attas OS, et al. Telomere length in relation to insulin resistance, inflammation and obesity among Arab youth. Acta Paediatr. 2010;99(6):896–9.CrossRefPubMed Al-Attas OS, et al. Telomere length in relation to insulin resistance, inflammation and obesity among Arab youth. Acta Paediatr. 2010;99(6):896–9.CrossRefPubMed
78.
Zurück zum Zitat O’Donnell CJ, et al. Leukocyte telomere length and carotid artery intimal medial thickness: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2008;28(6):1165–71.CrossRefPubMedPubMedCentral O’Donnell CJ, et al. Leukocyte telomere length and carotid artery intimal medial thickness: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2008;28(6):1165–71.CrossRefPubMedPubMedCentral
79.
Zurück zum Zitat Panayiotou AG, et al. Leukocyte telomere length is associated with measures of subclinical atherosclerosis. Atherosclerosis. 2010;211(1):176–81.CrossRefPubMed Panayiotou AG, et al. Leukocyte telomere length is associated with measures of subclinical atherosclerosis. Atherosclerosis. 2010;211(1):176–81.CrossRefPubMed
80.
Zurück zum Zitat Willeit P, et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol. 2010;30(8):1649–56.CrossRefPubMed Willeit P, et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol. 2010;30(8):1649–56.CrossRefPubMed
81.
Zurück zum Zitat Bischoff C, et al. No association between telomere length and survival among the elderly and oldest old. Epidemiology. 2006;17(2):190–4.CrossRefPubMed Bischoff C, et al. No association between telomere length and survival among the elderly and oldest old. Epidemiology. 2006;17(2):190–4.CrossRefPubMed
82.
Zurück zum Zitat Houben JM, et al. Telomere length and mortality in elderly men: the Zutphen Elderly Study. J Gerontol A Biol Sci Med Sci. 2011;66(1):38–44.CrossRefPubMed Houben JM, et al. Telomere length and mortality in elderly men: the Zutphen Elderly Study. J Gerontol A Biol Sci Med Sci. 2011;66(1):38–44.CrossRefPubMed
83.
Zurück zum Zitat Martin-Ruiz CM, et al. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell. 2005;4(6):287–90.CrossRefPubMed Martin-Ruiz CM, et al. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell. 2005;4(6):287–90.CrossRefPubMed
84.
Zurück zum Zitat Strandberg TE, et al. Association of telomere length in older men with mortality and midlife body mass index and smoking. J Gerontol A Biol Sci Med Sci. 2011;66(7):815–20.CrossRefPubMed Strandberg TE, et al. Association of telomere length in older men with mortality and midlife body mass index and smoking. J Gerontol A Biol Sci Med Sci. 2011;66(7):815–20.CrossRefPubMed
85.
Zurück zum Zitat Masi S, et al. Rate of telomere shortening and cardiovascular damage: a longitudinal study in the 1946 British Birth Cohort. Eur Heart J. 2014;35(46):3296–303.CrossRefPubMedPubMedCentral Masi S, et al. Rate of telomere shortening and cardiovascular damage: a longitudinal study in the 1946 British Birth Cohort. Eur Heart J. 2014;35(46):3296–303.CrossRefPubMedPubMedCentral
86.
Zurück zum Zitat Haycock PC, et al. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. Br Med J. 2014;349:g4227.CrossRef Haycock PC, et al. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. Br Med J. 2014;349:g4227.CrossRef
87.
Zurück zum Zitat Codd V, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet. 2013;45(4):422–7, 427e1–2. Codd V, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet. 2013;45(4):422–7, 427e1–2.
88.
Zurück zum Zitat I.R.G.C.E.R.F. Collaboration, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205–13.CrossRef I.R.G.C.E.R.F. Collaboration, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205–13.CrossRef
89.
Zurück zum Zitat Harrison SC, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J. 2013;34(48):3707–16.CrossRefPubMed Harrison SC, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J. 2013;34(48):3707–16.CrossRefPubMed
90.
Zurück zum Zitat Interleukin-6 Receptor Mendelian Randomisation Analysis Consortium, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379(9822):1214–24.CrossRef Interleukin-6 Receptor Mendelian Randomisation Analysis Consortium, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379(9822):1214–24.CrossRef
91.
Zurück zum Zitat Paige E, et al. Interleukin-6 receptor signaling and abdominal aortic aneurysm growth rates. Circ Genomic Precis Med. 2019;12(2):e002413.CrossRef Paige E, et al. Interleukin-6 receptor signaling and abdominal aortic aneurysm growth rates. Circ Genomic Precis Med. 2019;12(2):e002413.CrossRef
92.
Zurück zum Zitat Kranzhofer R, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19(7):1623–9.CrossRefPubMed Kranzhofer R, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19(7):1623–9.CrossRefPubMed
93.
Zurück zum Zitat Wu J, et al. The role of oxidative stress and inflammation in cardiovascular aging. BioMed Res Int. 2014;2014:615312.PubMedPubMedCentral Wu J, et al. The role of oxidative stress and inflammation in cardiovascular aging. BioMed Res Int. 2014;2014:615312.PubMedPubMedCentral
94.
Zurück zum Zitat Rodier F, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973–9.CrossRefPubMedPubMedCentral Rodier F, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973–9.CrossRefPubMedPubMedCentral
95.
Zurück zum Zitat Botto N, et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res. 2001;493(1–2):23–30.CrossRefPubMed Botto N, et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res. 2001;493(1–2):23–30.CrossRefPubMed
96.
Zurück zum Zitat Mahmoudi M, et al. Statins use a novel Nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repair in vascular smooth muscle cells. Circ Res. 2008;103(7):717–25.CrossRefPubMed Mahmoudi M, et al. Statins use a novel Nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repair in vascular smooth muscle cells. Circ Res. 2008;103(7):717–25.CrossRefPubMed
97.
Zurück zum Zitat Martinet W, et al. Oxidative DNA damage and repair in experimental atherosclerosis are reversed by dietary lipid lowering. Circ Res. 2001;88(7):733–9.CrossRefPubMed Martinet W, et al. Oxidative DNA damage and repair in experimental atherosclerosis are reversed by dietary lipid lowering. Circ Res. 2001;88(7):733–9.CrossRefPubMed
98.
Zurück zum Zitat Martinet W, et al. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation. 2002;106(8):927–32.CrossRefPubMed Martinet W, et al. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation. 2002;106(8):927–32.CrossRefPubMed
99.
Zurück zum Zitat Morgan RG, et al. Age-related telomere uncapping is associated with cellular senescence and inflammation independent of telomere shortening in human arteries. Am J Physiol Heart Circ Physiol. 2013;305(2):H251–8.CrossRefPubMedPubMedCentral Morgan RG, et al. Age-related telomere uncapping is associated with cellular senescence and inflammation independent of telomere shortening in human arteries. Am J Physiol Heart Circ Physiol. 2013;305(2):H251–8.CrossRefPubMedPubMedCentral
100.
Zurück zum Zitat Gardner SE, et al. Senescent vascular smooth muscle cells drive inflammation through an interleukin-1alpha-dependent senescence-associated secretory phenotype. Arterioscler Thromb Vasc Biol. 2015;35(9):1963–74.CrossRefPubMedPubMedCentral Gardner SE, et al. Senescent vascular smooth muscle cells drive inflammation through an interleukin-1alpha-dependent senescence-associated secretory phenotype. Arterioscler Thromb Vasc Biol. 2015;35(9):1963–74.CrossRefPubMedPubMedCentral
101.
Zurück zum Zitat Ridker PM, et al. antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.CrossRefPubMed Ridker PM, et al. antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.CrossRefPubMed
103.
Zurück zum Zitat Steensma DP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9–16.CrossRefPubMedPubMedCentral Steensma DP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9–16.CrossRefPubMedPubMedCentral
106.
Zurück zum Zitat Sano S, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 inflammasome. J Am Coll Cardiol. 2018;71(8):875–86.CrossRefPubMedPubMedCentral Sano S, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 inflammasome. J Am Coll Cardiol. 2018;71(8):875–86.CrossRefPubMedPubMedCentral
107.
Zurück zum Zitat Dorsheimer L, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4(1):25–33.CrossRefPubMed Dorsheimer L, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4(1):25–33.CrossRefPubMed
Metadaten
Titel
Inflammation and Vascular Ageing: From Telomeres to Novel Emerging Mechanisms
verfasst von
Martina Chiriacò
Georgios Georgiopoulos
Emiliano Duranti
Luca Antonioli
Ilaria Puxeddu
Monica Nannipieri
Javier Rosada
Corrado Blandizzi
Stefano Taddei
Agostino Virdis
Stefano Masi
Publikationsdatum
01.08.2019
Verlag
Springer International Publishing
Erschienen in
High Blood Pressure & Cardiovascular Prevention / Ausgabe 4/2019
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI
https://doi.org/10.1007/s40292-019-00331-7

Weitere Artikel der Ausgabe 4/2019

High Blood Pressure & Cardiovascular Prevention 4/2019 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.